newsfilter
← Latest News
Business Wire·

Acceleron Announces Second Quarter 2021 REBLOZYL® Net Sales

- Acceleron expects to report approximately $25.6 million in royalty revenue for Q2 2021 from approximately $128 million in net sales of REBLOZYL® (luspatercept-aamt) as reported by Bristol Myers Squibb - Acceleron Pharma Inc. (NASDAQ:XLRN), a bioph